Methods relating to intestinal organ-on-a-chip

Patent metadata

Field	Value
Publication number	US-12104174-B2
Application number	US-201716331718-A
Country	US
Kind code	B2
Filing date	Sep 13, 2017
Priority date	Sep 13, 2016
Publication date	Oct 1, 2024
Grant date	Oct 1, 2024

Abstract

Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.

First claim

What is claimed herein is:

1. A method of providing an in vitro intestinal model system, the method comprising:
a) providing i) an intestinal enteroid or colonoid comprising primary intestinal epithelial cells, ii) a microfluidic culture device, the device comprising a porous membrane having first and second surfaces, said membrane in fluidic communication with a microchannel, said microchannel in fluidic communication with a source of fluid;
b) disrupting said intestinal enteroid or colonoid comprising primary intestinal epithelial cells into enteroid or colonoid fragments;
c) seeding said second surface of said porous membrane with said enteroid or colonoid fragments so as to create seeded primary intestinal epithelial cells;
d) expanding said seeded primary intestinal epithelial cells so as to create a monolayer of the intestinal epithelial cells; and
e) exposing said monolayer to a fluid from said source of fluid at a flow rate, wherein said flow results in differentiation of the monolayer of the intestinal epithelial cells and the formation of intestinal villi comprising differentiated intestinal epithelial cells.

2. The method of claim 1 , the method further comprising: providing intestinal endothelial cells on said first surface of said porous membrane.

3. The method of claim 1 , wherein at least one of said differentiated intestinal epithelial cell types exhibits mucus secretion.

4. The method of claim 1 , wherein step b) comprises disrupting in the presence of a ROCK inhibitor.

5. The method of claim 4 , wherein the ROCK inhibitor is Y27632.

6. The method of claim 1 , wherein the method further comprises: step e) differentiating said monolayer of intestinal epithelial cells so as to create two or more different differentiated intestinal cell types.

7. The method of claim 6 , further comprising step f) differentiating said monolayer of intestinal epithelial cells so as to create two or more different differentiated intestinal cell types, wherein said two or more different differentiated intestinal cell types are selected from the group consisting of absorptive enterocytes, Paneth cells, goblet cells and enteroendocrine cells.

8. The method of claim 1 , wherein the method further comprises step f) maintaining the culture of the differentiated intestinal epithelial cells.

9. The method of claim 8 , wherein the maintaining step comprises providing the differentiated intestinal epithelial cells with expansion medium comprising one or more of the following: Wnt-3A; EGF; Rspo1; Noggin; gastrin; TGF-receptor inhibitor; and p38 MAPK inhibitor.

10. The method of claim 8 , wherein the maintaining step comprises providing the differentiated intestinal epithelial cells with expansion medium comprising Wnt-3A; EGF; Rspo1; Noggin; gastrin; TGF-receptor inhibitor; and p38 MAPK inhibitor.

11. The method of claim 1 , the method further comprising: providing fibroblasts.

12. The method of claim 11 , wherein said fibroblasts are cultured with said differentiated intestinal epithelial cells.

13. The method of claim 11 , wherein said fibroblasts are cultured on a gel on the first surface of the porous membrane.

14. The method of claim 1 , wherein the differentiated epithelial cells exhibit polarized distribution of one or more transporters following the expansion step.

15. The method of claim 1 , wherein the method further comprises contacting the differentiated intestinal epithelial cells with bacterial cells of one or more species.

16. The method of claim 15 , wherein the method further comprises co-culturing the differentiated intestinal epithelial cells and bacterial cells for at least 48 hours.

17. The method of claim 1 , further comprising step (f) forming said intestinal villi at a reproducibility that is at least twice the reproducibility as when seeding said second surface of said porous membrane with single cells that had been dissociated from said enteroids.

18. A method of providing an in vitro intestinal model system, the method comprising:
a) providing an intestinal microfluidic culture device, the device comprising a porous membrane wherein said membrane comprises a first and a second surface;
b) providing i) a sample of intestinal epithelial tissue, wherein said intestinal epithelial tissue comprises intestinal epithelial cells associated with intestinal crypts, ii) one or more extracellular-matrix degrading enzymes, and iii) a hydrogel;
c) washing said sample of intestinal epithelial tissue;
d) removing any associated muscle or mucosa layers from said intestinal epithelial tissue and then placing said intestinal epithelial tissue in a solution;
e) contacting said tissue with said one or more extracellular-matrix degrading enzymes, thereby releasing said intestinal crypts from said tissue into said solution;
f) removing said intestinal crypts from said solution then culturing said intestinal crypts in said hydrogel in the presence of Wnt3A, R-spondin, Noggin, and EGF to form an intestinal enteroid and/or colonoid;
g) disrupting the intestinal enteroid and/or colonoid comprising intestinal epithelial cells into enteroid and/or colonoid fragments comprising intestinal epithelial cells in the presence of a ROCK inhibitor;
h) establishing a culture of intestinal epithelial cells on the second surface of the porous membrane of the intestinal microfluidic culture device by contacting the second surface with the enteroid and/or colonoid fragments comprising intestinal epithelial cells resulting from step g; and
i) maintaining the culture of the intestinal epithelial cells in the intestinal microfluidic culture device by providing culture medium under continuous flow, wherein said flow is associated with morphological and functional differentiation of the intestinal epithelial cells, wherein said differentiation of the intestinal epithelial cells comprises differentiation of the cells to at least two or more of: absorptive enterocytes, Paneth cells, goblet cells, and enteroendocrine cells, wherein at least one of said differentiated intestinal epithelial cells exhibits mucus secreting capacity.

19. The method of claim 18 , wherein said culture medium is under continuous flow for at least 12 days of culture.

20. The method of claim 18 , further comprising establishing a culture of intestinal endothelial cells on the first surface of the porous membrane concurrently with establishing the culture of intestinal epithelial cells on a second surface of the porous membrane.

21. The method of claim 18 , wherein the method further comprises exposing the differentiated intestinal epithelial cells to an agent.

22. The method of claim 21 , wherein said agent is a candidate intestinal effector agent.

23. The method of claim 22 , wherein the method further comprises measuring a response of the differentiated intestinal epithelial cells to determine an effect of said candidate intestinal effector agent.

24. The method of claim 18 , wherein the ROCK inhibitor is Y27632.

25. The method of claim 18 , wherein the differentiated intestinal epithelial cells exhibit polarized distribution of one or more transporters following the maintaining step.

26. The method of claim 25 , wherein the one or more transporters are NHE3 and Na+/K+-ATPase.

27. The method of claim 26 , wherein the differentiated intestinal epithelial cells comprise a brush border membrane and a basolateral membrane, and wherein pol

Assignees

• Harvard College

Inventors

• Ingber Donald E
• Kasendra Magdalena
• Sontheimer-Phelps Alexandra
• Tovaglieri Alessio

Classifications

• G01N33/5088

  of vertebrates · CPC title

• C12N2502/1323

  Adult fibroblasts · CPC title

• C12N2501/415

  Wnt; Frizzeled · CPC title

• C12N2501/345

  Gastrin; Cholecystokinins [CCK] · CPC title

• C12N2501/11

  Epidermal growth factor [EGF] · CPC title